Especialidad: Reumatología
Páis: Estados Unidos

EDUCATION

Medical School Universidad Salvadoreña Alberto Masferrer (USAM) — 1991

PROFESSIONAL EXPERIENCE

Private Practice — Lake Charles, LA
Rheumatologist
July 2001 – Current

Clinical Director: New days Rehabilitation
Clinical Director
Dec 2001 – Dec 2002

Rheumatology fellow: Louisiana State University Medical Center — Baton Rouge, LA
Rheumatology Fellow
June 1996 – June 1999

Residency: Mount Vernon Hospital, affiliated to New York Medical College — Mt. Vernon, NY
Internal Medicine Resident
July 1994 – June 1996

Internship: Mount Vernon Hospital, affiliated to New York Medical College — Mt. Vernon, NY
Internal Medicine Intern
July 1993 – June 1994

PROFESSIONAL EXPERIENCE (El Salvador, Central America)

Private practice — El Salvador, Central America
Rheumatologist
July 1999 – June 2001

Hospital Nacional Zacamil — El Salvador, Central America
Rheumatology Consulting staff
July 1999 – June 2001

Hospital Militar Central — El Salvador, Central America
Rheumatology Consulting Staff
July 1999 – June 2001

Hospital Nacional de Maternidad — El Salvador, Central America
Internal Medicine Consulting Staff
July 1999 – June 2001

Internal Medicine House Officer, Instituto Salvadoreño del Seguro Social
June 1992 – June 1993

Internal Medicine House Officer, Baldwin Hospital
Jan 1992 – May 1992

Compulsory Rural Practice, Comasagua, El Salvador, Central America
June 1990 – Dec 1991

CERTIFICATIONS

CITI GCP Exp 26-Aug-2028
American Board of Internal Medicine – 1996
American Board of Rheumatology – 1999

LICENSURE

Louisiana Medical License #MD.024079 expires 30Jun2026

HONORS AND ACTIVITIES

Universidad Salvadoreana Alberto Masferrer Honor Scholarship 1986–1988

Universidad Salvadoreana Alberto Masferrer Student Award 1986–1988

1st Place, Scientific Research Paper at the Central America and Panama Medical Students Congress and National Congress of Medical Students of El Salvador 1988

Trainee Award, Southern Section of the American Federation of Medical Research and Southern Society for Clinical Investigation 1998

Rheumatology Fellow Award, American College of Rheumatology 1999

PRESENTATIONS

Trauma craneano en el Hospital Santa Teresa. Central America and Panama Medical Students Congress and National Congress of Medical Students of El Salvador. San Salvador, El Salvador, Central America.
March 1988

Renal Involvement in Juvenile Rheumatoid Arthritis: Report of two cases. Southern Section of the American Federation of Medical Research and Southern Society for Clinical Investigation. New Orleans, Louisiana.
February 1999

Arthrocentesis and Injection Techniques. American College of Physicians and American Society of Internal Medicine, Annual Session. New Orleans, Louisiana.
April 1999

Joint Examination and Injection Techniques. High Impact Rheumatology for Primary Care Physicians. New Orleans, Louisiana.
June 1999

Merck Sharp & Dohme. El Salvador, Central America
July 1999

Schering-Plough, S.A. El Salvador, Central America
July 1999

Novartis. Lake Charles, Louisiana, United States
2008

PUBLICATIONS

Elena Cucurull, Azzuddin E. Gharavi, Erdal Diri, Enrique A. Mendez, Dimpy Kapoor, Luis R, Espinoza. “IgA anticardiolipin and anti-B2-Glycoprotein I are the most prevalent isotype in African American Patients with SLE” Am J Med Science 1999 July, 318 (1) 55-60

Kelly L. Cobb, Enrique A. Mendez, Luis R, Espinoza. “Gouty Arthritis Mimicking Rheumatoid Arthritis” Journal of Clinical Rheumatology 1998:4, 225-228

Juan Angulo, Enrique A. Mendez, Luis R. Espinoza. “Arthritis Infecciosa” Medico Inter-Americano 1998; 17: 572-576 (Spanish)

JH Ponce de Leon, J Angulo, EA Mendez, LR Espinoza. “Algoritmo para el manejo de glomerulonephritis Lupica” Boletin do CIAR 1999: Col 1x 13-16 (Spanish)

EA Mendez, LM Espinoza, M Harris, J Angulo, CV Sanders and Luis R. Espinoza. “Systemic Lupus Erythematosus Complicated by Necrotizing Fasciitis” Lupus 1999; 8: 157-159

E Cucurull, LR Espinoza, E Mendez, JF Nolina, J Molina, J Ordi-Ros, AE Gharavi. “Anticardiolipin and anti-B2Glycoprotein-I antibodies in patients with systemic lupus erythematosus” Comparison between Colombians and Spaniards Lupus 1999; 8: 134-414

E A Mendez, J H Ponce de Leon, M L Cuellar, J Angelo, M A Guzman, E Hoffman, L R Espinoza. “Renal Outcome in African American (AA) patients with biopsy proven lupus nephritis: response to Therapy” Journal of the National Medical Association (in press) 1999

Enrique A. Mendez, Abraham Dedalia, Randall Craver, Matti Vehkashari, Luis R. Espinoza. “Renal Involvement in Juvenile Rheumatoid Arthritis: report of two cases” Journal of Clinical Rheumatology (Submitted) 1999

Dimpy Kapoor, MD; Enrique Mendez, MD Luis R. Espinoza, MD. “Letter to the Editor: Corticosteroid and SLE Pancreatitis: A Case Series” J Rheumatology 1999 April; 26 (4): 101-2

Diri E, Cucurull E, Gharavi AE, Kapoor D, Mendez, EA, Scopelitis E, Wilson WA. “Antiphospholipid (Hughes) Syndrome in African Americans: IgA aCL and antiB2Glycoprotein-I is the predominant isotype” Lupus 1999; 8(4): 263-8.

Enrique A. Mendez MD, Karen D DeSalvo, Yan Cao, MD, Robert F Garry, PhD and Luis R. Espinoza, MD. “A family with erosive arthritis and serum antibodies reactive with proteins associated with the human extracellular retroviral Particle Type I (HLA-P)”

Enrique A. Mendez MD, Luis R. Espinoza MD. “Manifestaciones extrahepaticas de la hepatitis C cronica” Boletime do C.I.A.R. (in press) 1999 (Spanish)

EA Mendez, An Iglesias-Gamarra, C Jimenez, C Canas, J Restrepo, M Pena, R Valle, LR Espinoza. “Poststreptococcal Reactive Arthritis (PSReA): A District Entity from Acute Rheumatic Fever” Annals of The Rheumatic Disease (in press) 2000

Enrique A. Mendez, Salvador Scermeno, Jose H Ponce de Leon, Juan Angulo, Miguel A. Guzman, Luis R. Espinoza. “dsDNA measured by crithidia does not correlate with renal disease in African Americans SLE patients” Journal of The National Medical Association (submitted) 2000

PROFESSIONAL MEMBERSHIP

Colegio de Medicina de El Salvador

Salvador American Medical Society

Fellow American College of Physicians

Fellow American College of Rheumatology

Sociedad Salvadoreña de Reumatología

Arthritis Foundation Louisiana Chapter

Louisiana State Medical Society

CLINICAL RESEARCH

Principal Investigator, 2025: Abbvie M23-699 A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderate to Severely Active SLE

Principal Investigator, 2025: Abbvie M25-05 A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis.

Principal Investigator, 2025: Biogen 230LE304 (TOPAZ) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Principal Investigator, 2025: Novartis CVAY736K12301 A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of lanalumab on top of standard-of-care therapy in participants with active lupus nephritis (SIRIUS-LN)

Principal Investigator, 2025: Orthotropix TPX-100-6 A Randomized, Double-blind, Placebo-controlled, 52-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects with Mild to Severe Tibio-Femoro Osteoarthritis of the Knee

Principal Investigator, 2025: Novartis Pharmaceutical CVAY736F12301E1 Trial entitled: A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of lanalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)

Principal Investigator, 2024: Takeda Development Center Americas – TAK-279-PsA-3001 A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

Principal Investigator, 2024: Argenx BV – ARGX-113-2306 A Phase 3 Randomized, Double-Blinded, Placebo Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease

Principal Investigator, 2024: MoonLake Immunotherapeutics AG – M1095-PSA-301 A Phase 3, parallel-group, randomized, double-blind, 3-arm, placebo controlled, multicenter study to investigate the efficacy and safety of subcutaneous Sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis who are naïve to biologic DMARDs

Principal Investigator, 2024: MoonLake Immunotherapeutics AG – M1095-PSA-302 A Phase 3, parallel-group, randomized, double-blind, 4-arm, placebo controlled, multicenter study to investigate the efficacy and safety of subcutaneous Sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitors

Principal Investigator, 2024: Biogen 303 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants with active systemic lupus erythematosus receiving background nonbiologic lupus standard of care

Principal Investigator, 2024: Merck 006-02 A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus

Principal Investigator, 2024: Lilly RHDB efficacy and safety of Ixekizumab or Ixekizumab concomitantly administered with Tinzaparin in adult participants with active psoriatic arthritis and obesity or overweight: a phase 3b, randomized, multicenter, open-label study (together-psa)

Principal Investigator, 2024: Lilly FTAF An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis

Principal Investigator, 2024: Zenas ZB012-02-001 A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Obexelimab in patients with systemic lupus erythematosus

Principal Investigator, 2024: Idorsia 303 A Phase 3 multicenter, open-label, single-arm extension study to evaluate the long-term safety and tolerability of Cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Principal Investigator, 2024: Kiniksa Pharmaceuticals – KPL-404-c221 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

Principal Investigator, 2024: HZNP-DAZ-301 A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

Principal Investigator, 2023: 2021-PT055: Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natruximab in Combination with Methotrexate for the Treatment of Rheumatoid Arthritis (NCT05363891)

Principal Investigator, 2023: Protocol No.: CVAY736F1230 Novartis Pharmaceutical Trial entitled: A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of Lanalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)

Principal Investigator, 2023: KPL-404-C211 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Arthritis with Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Principal Investigator, 2023: D7000C00001. A Phase I/III Randomized, Double blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment Brief Title: Study Understanding Pre-Exposure Prophylaxis of Novel Antibodies (SUPERKOVA)

Principal Investigator, 2023: ID 061A301: A Phase 3, multicenter, randomized, double Blind, placebocontrolle4 parallel group study to evaluate the efficacy safety and tolerability of Cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy.

Principal Investigator, 2022: Sun Pharma TILD-21-01, An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis TILD-21-01

Principal Investigator, 2022: UCB SL004, A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus. – SL0044

Principal Investigator, 2022: UCB SL0046, A multicenter, open-label extension study to assess the long-term Safety and Tolerability of Dapirolizumab Pegol treatment in study participants with systemic Lupus Erythematosus. – SL0046

Principal Investigator, 2022: Lilly J1A-MC-KDAF, A Phase 2b, Double-Blind, Placebo-Controlled Study to evaluate Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis

Principal Investigator, 2022: VIB1116.P1.S1: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC)- and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases

Principal Investigator, 2022: 4858-202: A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects with Active Psoriatic Arthritis

Principal Investigator, 2021: NETWORK-005: INFORMing Therapy Selection for JAK, T-Cell, Anti-CD20, or Anti-IL-6 Inhibitor Therapies, using a Molecular Signature Response Classifier (INFORM)

Principal Investigator, 2021: Sun Pharma TILD-19-19: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects with Active Psoriatic Arthritis II (INSPIRE 2) TILD-19-19

Principal Investigator, 2021: Sun Pharma TILD-19-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1) TILD-19-07

Principal Investigator, 2021: Scipher RA-003: Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis

Principal Investigator, 2021: Amgen, 2021 A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Systemic Lupus Erythematosus with Inadequate Response to Standard of Care Therapy Protocol number: 20200234 IND#131270

Principal Investigator, Crescendo 113-CL-01, 2020: Vectra Involved informed decision outcome study (VIVID): A prospective randomized controlled trial evaluation the effect of guided care with Vectra compared to treatment as usual in patients with Rheumatoid Arthritis.

Principal Investigator, UCB 43, 2020: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus. – SL0043

Principal Investigator, 2019: J4V-MC-JAJA (RA-BRIDGE) A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Sub-Investigator. Schering-Plough. Compassionate use of Anti-TNF chimeric monoclonal antibody (REMICADE) in the treatment of patients with active rheumatoid arthritis despite Methotrexate treatment
2000

Sub-Investigator. Hoffmann, LaRoche. A double blind, randomized, placebo-controlled study to evaluate the safety and efficacy of Ro 32-3555 (TROCADE) as adjunct to background anti-rheumatoid therapy, in preventing structural damage in rheumatoid arthritis. Protocol: WA 15541/B. 1999

Sub-Investigator. RW Johnson Pharmaceutical Research Institute. A randomized double blind, active and placebo controlled parallel group, dose response study of anti-inflammatory activity, safety and pharmacokinetics of RWJ-57504 in subjects with rheumatoid arthritis. Protocol 57504-RA-001. 1999

Sub-Investigator. Hoffman LaRoche. 24 Week trial of Ro 113-0830 in patients with primary knee osteoarthritis with or without rheumatoid osteoarthritis
1999

Sub-Investigator. G.D. Searle, Co., Inc. Multi-center double blind placebo control study of SC-65872 in rheumatoid arthritis.
1998

Sub-Investigator. Abbott la Jolla Pharmaceutical. Multi-Center double blind placebo control study of LJP-394 in Anti-dsDNA positive lupus nephritis
1998

Sub-Investigator. G.D. Searle, Co., Inc. Multi-center double blind placebo-controlled comparison study of the efficacy of SC-58635 200 mg QD versus SC58635 in treating the signs and symptoms of osteoarthritis of the knee, IND#48,395 (N49-98-02-087)
1998

Sub-Investigator. SmithKline Beecham. Multi-center double blind, placebo control study of SB-210396 in active rheumatoid arthritis.
1997

Sub-Investigator. G.D. Searle, Co., Inc. Multi-center long-term safety study of SC-58635 in osteoarthritis and rheumatoid arthritis
1996